Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

The association of birthweight with age at natural menopause: a population study of women in Norway.

Bjelland EK, Gran JM, Hofvind S, Eskild A.

Int J Epidemiol. 2019 Oct 21. pii: dyz207. doi: 10.1093/ije/dyz207. [Epub ahead of print]

PMID:
31633179
2.

Terminal digit preference: a source of measurement error in breast cancer diameter reporting.

Tsuruda KM, Hofvind S, Akslen LA, Hoff SR, Veierød MB.

Acta Oncol. 2019 Sep 30:1-8. doi: 10.1080/0284186X.2019.1669817. [Epub ahead of print]

PMID:
31566467
3.

Screening at stationary versus mobile units in BreastScreen Norway.

Holen Å, Sebuødegård S, Waade GG, Aase H, Hopland NM, Pedersen K, Larsen M, Tsuruda KM, Hofvind S.

J Med Screen. 2019 Sep 25:969141319875158. doi: 10.1177/0969141319875158. [Epub ahead of print] No abstract available.

PMID:
31554445
4.

Gender, letters, relatives, and God: mediating actors in mammographic screening among Pakistani women in Norway.

Bhargava S, Hofvind S, Moen K.

Acta Radiol Open. 2019 Sep 11;8(9):2058460119875015. doi: 10.1177/2058460119875015. eCollection 2019 Sep.

5.

Pathway times in the mammography programme before and after introduction of the breast cancer care pathway.

Tsuruda KM, Bhargava S, Akslen LA, Bjørndal H, Hofvind S.

Tidsskr Nor Laegeforen. 2019 Sep 9;139(12). doi: 10.4045/tidsskr.18.0322. Print 2019 Sep 10. Norwegian.

6.

Cost differences between digital tomosynthesis and standard digital mammography in a breast cancer screening programme: results from the To-Be trial in Norway.

Moger TA, Swanson JO, Holen ÅS, Hanestad B, Hofvind S.

Eur J Health Econ. 2019 Nov;20(8):1261-1269. doi: 10.1007/s10198-019-01094-7. Epub 2019 Aug 9.

7.

Number of Risky Lifestyle Behaviors and Breast Cancer Risk.

Ellingjord-Dale M, Vos L, Vik Hjerkind K, Hjartåker A, Russnes HG, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G.

JNCI Cancer Spectr. 2018 Jul 19;2(3):pky030. doi: 10.1093/jncics/pky030. eCollection 2018 Jul.

8.

Breast compression parameters among women screened with standard digital mammography and digital breast tomosynthesis in a randomized controlled trial.

Waade GG, Holen Å, Sebuødegård S, Aase H, Pedersen K, Hanestad B, Hofvind S.

Acta Radiol. 2019 Jul 25:284185119863989. doi: 10.1177/0284185119863989. [Epub ahead of print] No abstract available.

PMID:
31342757
9.

Methods for Development of the European Commission Initiative on Breast Cancer Guidelines: Recommendations in the Era of Guideline Transparency.

Schünemann HJ, Lerda D, Dimitrova N, Alonso-Coello P, Gräwingholt A, Quinn C, Follmann M, Mansel R, Sardanelli F, Rossi PG, Lebeau A, Nyström L, Broeders M, Ioannidou-Mouzaka L, Duffy SW, Borisch B, Fitzpatrick P, Hofvind S, Castells X, Giordano L, Warman S, Saz-Parkinson Z; European Commission Initiative on Breast Cancer Contributor Group.

Ann Intern Med. 2019 Jul 23. doi: 10.7326/M18-3445. [Epub ahead of print]

PMID:
31330534
10.

Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study.

Ponti A, Ronco G, Lynge E, Tomatis M, Anttila A, Ascunce N, Broeders M, Bulliard JL, Castellano I, Fitzpatrick P, Frigerio A, Hofvind S, Májek O, Segnan N, Taplin S; ICSN DCIS Working Group.

Breast Cancer Res Treat. 2019 Oct;177(3):761-765. doi: 10.1007/s10549-019-05333-6. Epub 2019 Jun 28.

PMID:
31250357
11.

Risk of breast cancer by prior screening results among women participating in BreastScreen Norway.

Lilleborge M, Falk RS, Russnes H, Sauer T, Ursin G, Hofvind S.

Cancer. 2019 Oct 1;125(19):3330-3337. doi: 10.1002/cncr.32330. Epub 2019 Jun 17.

PMID:
31206638
12.

Screening outcome for consecutive examinations with digital breast tomosynthesis versus standard digital mammography in a population-based screening program.

Hovda T, Brandal SHB, Sebuødegård S, Holen ÅS, Bjørndal H, Skaane P, Hofvind S.

Eur Radiol. 2019 Dec;29(12):6991-6999. doi: 10.1007/s00330-019-06264-y. Epub 2019 Jun 11.

PMID:
31187221
13.

Influence of Mammography Volume on Radiologists' Performance: Results from BreastScreen Norway.

Hoff SR, Myklebust TÅ, Lee CI, Hofvind S.

Radiology. 2019 Aug;292(2):289-296. doi: 10.1148/radiol.2019182684. Epub 2019 May 28.

PMID:
31135295
14.

Breast compression and experienced pain during mammography by use of three different compression paddles.

Moshina N, Sebuødegård S, Evensen KT, Hantho C, Iden KA, Hofvind S.

Eur J Radiol. 2019 Jun;115:59-65. doi: 10.1016/j.ejrad.2019.04.006. Epub 2019 Apr 14.

PMID:
31084760
15.

Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.

Hofvind S, Holen ÅS, Aase HS, Houssami N, Sebuødegård S, Moger TA, Haldorsen IS, Akslen LA.

Lancet Oncol. 2019 Jun;20(6):795-805. doi: 10.1016/S1470-2045(19)30161-5. Epub 2019 May 8. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31078459
16.

Digital Mammography versus Digital Mammography Plus Tomosynthesis in Breast Cancer Screening: The Oslo Tomosynthesis Screening Trial.

Skaane P, Bandos AI, Niklason LT, Sebuødegård S, Østerås BH, Gullien R, Gur D, Hofvind S.

Radiology. 2019 Apr;291(1):23-30. doi: 10.1148/radiol.2019182394. Epub 2019 Feb 19.

PMID:
30777808
17.

Performance measures among non-immigrants and immigrants attending BreastScreen Norway: a population-based screening programme.

Bhargava S, Akslen LA, Bukholm IRK, Hofvind S.

Eur Radiol. 2019 Sep;29(9):4833-4842. doi: 10.1007/s00330-019-6009-2. Epub 2019 Feb 14.

PMID:
30762109
18.

Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts.

Román M, Hofvind S, von Euler-Chelpin M, Castells X.

Br J Cancer. 2019 Jan;120(2):269-275. doi: 10.1038/s41416-018-0358-5. Epub 2018 Dec 19.

PMID:
30563993
19.

The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.

Broeders MJM, Allgood P, Duffy SW, Hofvind S, Nagtegaal ID, Paci E, Moss SM, Bucchi L.

BMC Cancer. 2018 Sep 3;18(1):860. doi: 10.1186/s12885-018-4666-1. Review.

20.

A randomized controlled trial of digital breast tomosynthesis versus digital mammography in population-based screening in Bergen: interim analysis of performance indicators from the To-Be trial.

Aase HS, Holen ÅS, Pedersen K, Houssami N, Haldorsen IS, Sebuødegård S, Hanestad B, Hofvind S.

Eur Radiol. 2019 Mar;29(3):1175-1186. doi: 10.1007/s00330-018-5690-x. Epub 2018 Aug 29.

21.

Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life.

Sandvei MS, Vatten LJ, Bjelland EK, Eskild A, Hofvind S, Ursin G, Opdahl S.

Eur J Epidemiol. 2019 Mar;34(3):267-278. doi: 10.1007/s10654-018-0431-7. Epub 2018 Aug 6.

PMID:
30083811
22.

Automated Volumetric Analysis of Mammographic Density in a Screening Setting: Worse Outcomes for Women with Dense Breasts.

Moshina N, Sebuødegård S, Lee CI, Akslen LA, Tsuruda KM, Elmore JG, Hofvind S.

Radiology. 2018 Aug;288(2):343-352. doi: 10.1148/radiol.2018172972. Epub 2018 Jun 26.

PMID:
29944088
23.

Breast compression across consecutive examinations among females participating in BreastScreen Norway.

Waade GG, Sebuødegård S, Hogg P, Hofvind S.

Br J Radiol. 2018 Oct;91(1090):20180209. doi: 10.1259/bjr.20180209. Epub 2018 Jul 13.

24.

Volumetric Mammographic Density, Age-Related Decline, and Breast Cancer Risk Factors in a National Breast Cancer Screening Program.

Hjerkind KV, Ellingjord-Dale M, Johansson ALV, Aase HS, Hoff SR, Hofvind S, Fagerheim S, Dos-Santos-Silva I, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1065-1074. doi: 10.1158/1055-9965.EPI-18-0151. Epub 2018 Jun 20.

25.

The relation of age at menarche with age at natural menopause: a population study of 336 788 women in Norway.

Bjelland EK, Hofvind S, Byberg L, Eskild A.

Hum Reprod. 2018 Jun 1;33(6):1149-1157. doi: 10.1093/humrep/dey078.

26.

Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Digital Mammography: Evaluation in a Population-based Screening Program.

Hofvind S, Hovda T, Holen ÅS, Lee CI, Albertsen J, Bjørndal H, Brandal SHB, Gullien R, Lømo J, Park D, Romundstad L, Suhrke P, Vigeland E, Skaane P.

Radiology. 2018 Jun;287(3):787-794. doi: 10.1148/radiol.2018171361. Epub 2018 Mar 1.

PMID:
29494322
27.

Mammographic screening attendance among immigrant and minority women: a systematic review and meta-analysis.

Bhargava S, Moen K, Qureshi SA, Hofvind S.

Acta Radiol. 2018 Nov;59(11):1285-1291. doi: 10.1177/0284185118758132. Epub 2018 Feb 16. Review.

PMID:
29451023
28.

Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial.

Skaane P, Sebuødegård S, Bandos AI, Gur D, Østerås BH, Gullien R, Hofvind S.

Breast Cancer Res Treat. 2018 Jun;169(3):489-496. doi: 10.1007/s10549-018-4705-2. Epub 2018 Feb 10.

PMID:
29429017
29.

Optimizing performance of BreastScreen Norway using value of information in graphical models.

Lilleborge M, Hofvind S, Sebuødegård S, Hauge R.

Stat Med. 2018 Apr 30;37(9):1531-1549. doi: 10.1002/sim.7601. Epub 2018 Feb 1.

PMID:
29388235
30.

Validity and reliability of self-reported health indicators among women attending organized mammographic screening.

Tsuruda KM, Sagstad S, Sebuødegård S, Hofvind S.

Scand J Public Health. 2018 Nov;46(7):744-751. doi: 10.1177/1403494817749393. Epub 2018 Jan 24.

PMID:
29366395
31.

The impact of compression force and pressure at prevalent screening on subsequent re-attendance in a national screening program.

Moshina N, Sebuødegård S, Holen ÅS, Waade GG, Tsuruda K, Hofvind S.

Prev Med. 2018 Mar;108:129-136. doi: 10.1016/j.ypmed.2018.01.008. Epub 2018 Jan 11.

PMID:
29337068
32.

Stage-specific incidence and survival of breast cancer in Norway: The implications of changes in coding and classification practice.

Larsen IK, Myklebust TÅ, Johannesen TB, Møller B, Hofvind S.

Breast. 2018 Apr;38:107-113. doi: 10.1016/j.breast.2017.12.001. Epub 2018 Jan 5.

PMID:
29306771
33.

Interval Breast Cancer Rates and Histopathologic Tumor Characteristics after False-Positive Findings at Mammography in a Population-based Screening Program.

Hofvind S, Sagstad S, Sebuødegård S, Chen Y, Roman M, Lee CI.

Radiology. 2018 Apr;287(1):58-67. doi: 10.1148/radiol.2017162159. Epub 2017 Dec 14.

PMID:
29239711
34.

Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway.

Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, de Lange T, Bagnardi V, Ursin G, Weiderpass E.

BMJ Open. 2017 Nov 15;7(11):e017639. doi: 10.1136/bmjopen-2017-017639.

35.

Breast compression parameters and mammographic density in the Norwegian Breast Cancer Screening Programme.

Moshina N, Roman M, Waade GG, Sebuødegård S, Ursin G, Hofvind S.

Eur Radiol. 2018 Apr;28(4):1662-1672. doi: 10.1007/s00330-017-5104-5. Epub 2017 Nov 2.

PMID:
29098437
36.

Lower attendance rates in immigrant versus non-immigrant women in the Norwegian Breast Cancer Screening Programme.

Bhargava S, Tsuruda K, Moen K, Bukholm I, Hofvind S.

J Med Screen. 2018 Sep;25(3):155-161. doi: 10.1177/0969141317733771. Epub 2017 Oct 23.

PMID:
29059006
37.

Monthly variation in mammographic screening attendance in Norway.

Tsuruda KM, Bhargava S, Mangerud G, Sagstad S, Hofvind SSH.

Eur J Public Health. 2017 Dec 1;27(6):1095-1097. doi: 10.1093/eurpub/ckx137.

PMID:
29036414
38.

Breast Cancer Screening in Denmark.

Bhargava S, Tsuruda K, Hofvind S.

Ann Intern Med. 2017 Oct 3;167(7):523. doi: 10.7326/L17-0269. No abstract available.

PMID:
28973199
39.

Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program.

Ellingjord-Dale M, Vos L, Hjerkind KV, Hjartåker A, Russnes HG, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1736-1744. doi: 10.1158/1055-9965.EPI-17-0611. Epub 2017 Sep 6.

40.

Dynamiske screeningprogrammer.

Ursin G, Hofvind S, Tropé A.

Tidsskr Nor Laegeforen. 2017 Aug 21;137(14-15). doi: 10.4045/tidsskr.17.0576. Print 2017 Aug 22. Norwegian. No abstract available.

PMID:
28828792
Free Article
41.

Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?

Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, Ursin G, Weiderpass E.

Int J Cancer. 2017 Nov 1;141(9):1763-1770. doi: 10.1002/ijc.30878. Epub 2017 Jul 19.

42.

Comparison of subjective and fully automated methods for measuring mammographic density.

Moshina N, Roman M, Sebuødegård S, Waade GG, Ursin G, Hofvind S.

Acta Radiol. 2018 Feb;59(2):154-160. doi: 10.1177/0284185117712540. Epub 2017 May 31.

PMID:
28565960
43.

Radiographers' opinions on radiography research in Norway - A national survey.

Vikestad KG, Hafskjold L, Kjelle E, Sebuødegård S, Hofvind S.

Radiography (Lond). 2017 May;23(2):135-140. doi: 10.1016/j.radi.2016.12.006. Epub 2017 Jan 17.

PMID:
28390545
44.

Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program?

Moshina N, Sebuødegård S, Hofvind S.

Breast Cancer Res Treat. 2017 Jun;163(3):605-613. doi: 10.1007/s10549-017-4214-8. Epub 2017 Mar 29.

PMID:
28357655
45.

Development of a phantom to test fully automated breast density software - A work in progress.

Waade GG, Hofvind S, Thompson JD, Highnam R, Hogg P.

Radiography (Lond). 2017 Feb;23(1):e14-e19. doi: 10.1016/j.radi.2016.09.003. Epub 2016 Oct 3.

PMID:
28290354
46.

Compression force and radiation dose in the Norwegian Breast Cancer Screening Program.

Waade GG, Sanderud A, Hofvind S.

Eur J Radiol. 2017 Mar;88:41-46. doi: 10.1016/j.ejrad.2016.12.025. Epub 2016 Dec 31.

PMID:
28189207
47.

Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.

Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G.

Breast Cancer Res. 2017 Jan 23;19(1):10. doi: 10.1186/s13058-016-0798-x.

48.

Compression forces used in the Norwegian Breast Cancer Screening Program.

Waade GG, Moshina N, Sebuødegård S, Hogg P, Hofvind S.

Br J Radiol. 2017 Mar;90(1071):20160770. doi: 10.1259/bjr.20160770. Epub 2017 Feb 17.

49.

Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries.

Román M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1464-1473. Epub 2016 Jul 26.

50.

Breast cancer incidence trends in Norway and estimates of overdiagnosis.

van Luijt PA, Heijnsdijk EA, van Ravesteyn NT, Hofvind S, de Koning HJ.

J Med Screen. 2017 Jun;24(2):83-91. doi: 10.1177/0969141316668379. Epub 2016 Oct 17.

PMID:
27754936

Supplemental Content

Loading ...
Support Center